At the news
? NEUTRALIMPACT 3/10 6-K filed May 8, 2026 at 09:10 ET
Alpha Tau Medical Ltd. filed a 6-K on May 8, 2026, announcing a conference call to discuss interim clinical data from the first three patients treated in its REGAIN trial for recurrent glioblastoma. The filing is a routine update on early-stage clinical progress with no financial data or material corporate events disclosed.
- Conference call scheduled for May 11, 2026 at 8:30am ET to discuss interim data from first three patients in REGAIN trial.
- REGAIN trial is a U.S. study for recurrent glioblastoma not amenable to surgical resection, expected to enroll up to ten patients.
- No financial results, guidance, or material agreements were disclosed in the filing.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access